Home  /  Resource Library  /  Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

ASH 2020: Results of a study examining everolimus combined with itacitnib for treatment of relapsed Hodgkin lymphoma.